Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 304, ahead of Merck & Co (140) and Ligand Pharmaceuticals (120). Figures as of 18 Nov 2026, 20:24 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical304
- Median
- 40.2
- Combined market value
- CHF 4.28T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 304 | CHF 57.4B | CHF 17.96 | 1.59% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 140 | CHF 288B | CHF 116.82 | 3.37% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 120 | CHF 5B | CHF 251.66 | 1.58% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.5 | CHF 8.4B | CHF 55.65 | 5.25% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.1 | CHF 41.5B | CHF 35.55 | 1.07% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 73.0 | CHF 13.3B | CHF 207.92 | 2.44% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | CHF 6.3B | CHF 80.10 | 0.12% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.5 | CHF 6.4B | CHF 18.38 | 3.20% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.8 | CHF 38.9B | CHF 340.37 | 2.32% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.2 | CHF 6.3B | CHF 57.36 | 2.91% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.2 | CHF 427.2B | CHF 241.67 | 2.12% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 45.2 | CHF 33.5B | CHF 58.27 | 0.62% up | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 45.1 | CHF 1.04T | CHF 1,170.37 | 1.95% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.7 | CHF 26.6B | CHF 43.13 | 1.56% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.7 | CHF 10.6B | CHF 12.66 | 1.49% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.6 | CHF 555.8B | CHF 230.89 | 1.75% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.2 | CHF 135.2B | CHF 23.72 | 1.21% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.2 | CHF 153.3B | CHF 88.53 | 0.27% up | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.6 | CHF 115B | CHF 453.76 | 0.74% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.6 | CHF 247.2B | CHF 130.88 | 2.46% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.8 | CHF 7B | CHF 106.75 | 1.55% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | CHF 234.2B | CHF 151.03 | 1.73% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.5 | CHF 95.5B | CHF 39.79 | 0.73% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.9 | CHF 20.8B | CHF 488.92 | 0.73% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | CHF 82.6B | CHF 798.23 | 1.16% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | CHF 15B | CHF 228.51 | 0.07% down | 28% up | ||
| 27 | GSKGSK · Health Care | 17.0 | CHF 82.4B | CHF 41.09 | 1.04% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.7 | CHF 29.6B | CHF 72.86 | 3.51% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.3 | CHF 103.3B | CHF 50.56 | 2.27% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | CHF 4.8B | CHF 7.13 | 2.09% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | CHF 146.6B | CHF 33.26 | 3.07% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | CHF 16.9B | CHF 126.05 | 4.48% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 5.0 | CHF 3.8B | CHF 35.01 | 1.24% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8432 CHF). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (304), Merck & Co (140) and Ligand Pharmaceuticals (120) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 20:24 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of CHF 4.28T as of 18 Nov 2026, 20:24 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.